Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Randomized, Placebo Controlled Trial of Withdrawal of Slow-acting Antirheumatic Drugs and of Observer Bias in Rheumatoid Arthritis

Randomized, Placebo Controlled Trial of Withdrawal of Slow-acting Antirheumatic Drugs and of... Patients with rheumatoid arthritis, in stable treatment with methotrexate, penicillamine, or sulfasalazine, were randomized in a double-blind fashion either to continuation of their usual treatment or to placebo. 112 patients were included; 52 patients who refused participation had no more severe disease than the others. The patients felt worse on placebo than on active drug (p = 0.002). The mean differences in number of tender, painful and swollen joints after one month were 2.4 (p=0.08), 3.0 (p = 0.I2) and 2.2 (p = 0.03), respectively. Treatment failure occurred for 42 patients of whom 33 received placebo (p = 0.000,001). There was no difference in the severity of side effects (p=0.91). The patients guessed their treatment correctly more often than expected (p=0.02) because of the perceived effect. None of the two observers guessed better than chance, and there were no differences between the observers' evaluations of the joints. The effect of slow-acting antirheumatic drugs was unequivocal and no observer bias occurred. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Scandinavian Journal of Rheumatology Taylor & Francis

Randomized, Placebo Controlled Trial of Withdrawal of Slow-acting Antirheumatic Drugs and of Observer Bias in Rheumatoid Arthritis

Randomized, Placebo Controlled Trial of Withdrawal of Slow-acting Antirheumatic Drugs and of Observer Bias in Rheumatoid Arthritis

Scandinavian Journal of Rheumatology , Volume 25 (4): 6 – Jan 1, 1996

Abstract

Patients with rheumatoid arthritis, in stable treatment with methotrexate, penicillamine, or sulfasalazine, were randomized in a double-blind fashion either to continuation of their usual treatment or to placebo. 112 patients were included; 52 patients who refused participation had no more severe disease than the others. The patients felt worse on placebo than on active drug (p = 0.002). The mean differences in number of tender, painful and swollen joints after one month were 2.4 (p=0.08), 3.0 (p = 0.I2) and 2.2 (p = 0.03), respectively. Treatment failure occurred for 42 patients of whom 33 received placebo (p = 0.000,001). There was no difference in the severity of side effects (p=0.91). The patients guessed their treatment correctly more often than expected (p=0.02) because of the perceived effect. None of the two observers guessed better than chance, and there were no differences between the observers' evaluations of the joints. The effect of slow-acting antirheumatic drugs was unequivocal and no observer bias occurred.

Loading next page...
 
/lp/taylor-francis/randomized-placebo-controlled-trial-of-withdrawal-of-slow-acting-cDEc4bGYNG

References (21)

Publisher
Taylor & Francis
Copyright
© 1996 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted
ISSN
1502-7732
eISSN
0300-9742
DOI
10.3109/03009749609069987
Publisher site
See Article on Publisher Site

Abstract

Patients with rheumatoid arthritis, in stable treatment with methotrexate, penicillamine, or sulfasalazine, were randomized in a double-blind fashion either to continuation of their usual treatment or to placebo. 112 patients were included; 52 patients who refused participation had no more severe disease than the others. The patients felt worse on placebo than on active drug (p = 0.002). The mean differences in number of tender, painful and swollen joints after one month were 2.4 (p=0.08), 3.0 (p = 0.I2) and 2.2 (p = 0.03), respectively. Treatment failure occurred for 42 patients of whom 33 received placebo (p = 0.000,001). There was no difference in the severity of side effects (p=0.91). The patients guessed their treatment correctly more often than expected (p=0.02) because of the perceived effect. None of the two observers guessed better than chance, and there were no differences between the observers' evaluations of the joints. The effect of slow-acting antirheumatic drugs was unequivocal and no observer bias occurred.

Journal

Scandinavian Journal of RheumatologyTaylor & Francis

Published: Jan 1, 1996

Keywords: rheumatoid arthritis; methotrexate; penicillamine; sulfasalazine; placebo; bias; observer variation

There are no references for this article.